Symbicort
Asthma/COPD
ApprovedCommercial
Key Facts
About AstraZeneca
AstraZeneca is one of the world's largest pharmaceutical companies, headquartered in Cambridge, UK, with a market capitalization of approximately $285 billion. The company focuses on transformative science including next-generation therapeutics, AI-driven drug discovery, and personalized medicine approaches. AstraZeneca reported strong commercial performance in 2025 with 16 positive Phase 3 study results announced during the year, demonstrating continued pipeline strength across multiple therapeutic areas.
View full company profileOther Asthma/COPD Drugs
| Drug | Company | Phase |
|---|---|---|
| ProAir (albuterol) | Teva Pharmaceutical Industries | Commercial |
| Generic ProAir (Albuterol HFA) | Lupin Limited | Approved |
| Generic Advair (Fluticasone/Salmeterol) | Lupin Limited | Phase 3 |
| Generic Symbicort | Lupin Limited | Development |
| Albuterol HFA | Cipla | Commercial |
| Generic Advair Equivalent | Cipla | Phase 3 |
| GRC 54276 | Glenmark Pharmaceuticals | Phase 2 |